Ulcerative colitis is a form of inflammatory bowel disease. It is a chronic relapsing condition affecting the colon and rectum and can cause a variety of symptoms, the commonest of which is bloody diarrhoea. Prompt diagnosis, as well as flare identification and management by primary care clinicians can improve patient outcomes such as disease progression and effects on quality of life.
Get full access to this article
View all access options for this article.
References
1.
BannagaASelingerC (2015) Inflammatory bowel disease and anxiety: Links, risks, and challenges faced. Clinical and Experimental Gastroenterology8: 111–117. DOI: 10.2147/CEG.S57982.
FrolkisADDykemanJNegronME, et al. (2013) Risk of surgery for inflammatory bowel diseases has decreased over time: A systematic review and meta-analysis of population-based studies. Gastroenterology145(5): 996–1006. DOI: 10.1053/j.gastro.2013.07.041.
4.
GoodhandRWahedMMawdsleyJ, et al. (2012) Mood disorders in inflammatory bowel disease: Relation to diagnosis, disease activity, perceived stress, and other factors. Inflammatory Bowel Disease18(12): 2301–2309. DOI: 10.1002/ibd.22916.
5.
HalfvarsonJBodinLTyskC, et al. (2003) Inflammatory bowel disease in a Swedish twin cohort: A long-term follow-up of concordance and clinical characteristics. Gastroenterology124(7): 1767–1773. DOI: 10.1016/S0016-5085(03)00385-8.
6.
KaneSHuoDAikensJ, et al. (2003) Medication non-adherence and the outcomes of patients with quiescent ulcerative colitis. The American Journal of Medicine114(1): 39–43. DOI: 10.1016/S0002-9343(02)01383-9.
7.
KarvellasCFedorakRHansonJ, et al. (2007) Increased incidence of colorectal cancer in ulcerative colitis patients diagnosed after 40 years of age. Canadian Journal of Gastroenterology21(7): 443–446. Available at: www.ncbi.nlm.nih.gov/pmc/articles/PMC2657965/ 9 (accessed 17 May 2019).
8.
LakatosPLakatosL (2008) Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies. World Journal of Gastroenterology14(25): 3937–3947. DOI: 10.3748/wjg.14.3937.
NgSShiHYHamidiN, et al. (2017) Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. The Lancet360(10114): 2769–2778. DOI: 10.1016/S0140-6736(17)32448-0.
SpehlmannMBergunABurghardtJ, et al. (2008) Epidemiology of inflammatory bowel disease in a German twin cohort: Results of a nationwide study. Inflammatory Bowel Diseases14(7): 968–976. DOI: 10.1002/ibd.20380.
20.
TurvillJO’ConnellSBrooksA (2016) Evaluation of a faecal calprotectin care pathway for the use in primary care. Primary Care Research Development17(5): 428–436. DOI: 10.1017/S1463423616000049.
21.
VavrickaSSchoepferAScharlM, et al. (2015) Extraintestinal manifestations of inflammatory bowel disease. Inflammatory Bowel Disease21(8): 1982–1992. DOI: 10.1097/MIB.0000000000000392.
22.
WaughNCumminsERoyleP (2013) Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: Systematic review and economic evaluation. Health Technology Assessment17(55): 1–211. DOI: 10.3310/hta17550.
23.
YeBvan LangenbergD (2015) Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?World Journal of Gastrointestinal Pharmacology and Therapeutics6(4): 137–144. DOI: 10.4292/wjgpt.v6.i4.137.
24.
ZhangY-ZLiY-Y (2014) Inflammatory bowel disease: Pathogenesis. World Journal of Gastroenterology20(1): 91–99. DOI: 10.3748/wjg.v20.i1.91.
